Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COV2 nasal COVID-19 vaccine at different doses and administration methods
NCT06851611Phase 1Completed
- Sponsor
- Rokote Laboratories Finland
- Start
- Jan 2025
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of COV2 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Rokote Laboratories Finland. Primary endpoints: Primary Immunogenicity at 28 days and Primary Safety at 28 days. Started Jan 2025; status: completed.
02
Drugs
COV2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06851611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851611.